world
3 known investors
Sparrow Pharma develops targeted cardiometabolic therapeutics for patients with type 2 diabetes, focusing on cortisol regulation through HSD-1 inhibition. The company's lead candidate, clofutriben, is designed to reduce intracellular cortisol levels to improve glycemic control in patients with treatment-resistant diabetes.